Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Market-Beating Community Intelligence
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Their genetic marker will be a big help to drugmakers targeting patients specifically receptive to their treatments. It may take a little longer than hoped because of choices the big pharmas made in how they test their therapies, but it ultimately seems Myriad will be the winner.The pullback gives investors a nice entry point here.